

Abstract Submission No.: A-0311


Successful Pregnancy In IgA Nephropathy Patient After Treatment With Telitacicept: Case Report

Xinru Du, Hongyu Yu, Lijun Wu, Xuehong Lu

Department of Internal Medicine-Nephrology, The Second Hospital of Jilin University, China, China

Case Study : Pregnant women with IgA nephropathy (IgAN) have a higher risk of miscarriage, low birth weight babies, and pre-eclampsia. Moreover, the level of proteinuria and Chronic Kidney Disease(CKD) during pregnancy are closely associated with adverse pregnancy outcomes. It is therefore especially critical for women with IgAN to have their condition under control before and during pregnancy. Conventional medications that can be used in pregnancy still have significant limitations, such as low complete remission rates, long treatment cycles, infection or other potential teratogens, and risk of recurrence. The novel biologic agent, Telitacicept, dual-targets Blys/BAFF, and APRIL to achieve full inhibition of B cells and plasma cells, resulting in rapid disease control and long-term remission. This provides a new disease treatment option for women with pregnancy needs who want to achieve sustained remission and reduces the incidence of adverse pregnancy events caused by disease progression or relapse. We report the case of a woman who had a successful pregnancy after treatment with Telitacicept and achieved a long and stable remission. This is the first report of Telitacicept in a pregnant woman, and we hope that it will provide a new safe, and effective treatment option for female patients in need of pregnancy.

figure.png



Changes in serum creatinine, urinary erythrocytes, urinary protein, dose of medicines